Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome

Fred S. Apple, Alan H.A. Wu, Johannes Mair, Jan Ravkilde, Mauro Panteghini, Jillian Tate, Franca Pagani, Robert H. Christenson, Martin Mockel, Oliver Danne, Allan S. Jaffe

Research output: Contribution to journalReview article

372 Scopus citations

Abstract

Background: Evaluation of patients who present to the hospital with a complaint of chest pain or other signs or symptoms suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and problematic. Recent investigations have indicated that increases in biomarkers upstream from biomarkers of necrosis (cardiac troponins I and T), such as inflammatory cytokines, cellular adhesion molecules, acute-phase reactants, plaque destabilization and rupture biomarkers, biomarkers of ischemia, and biomarkers of myocardial stretch may provide earlier assessment of overall patient risk and aid in identifying patients with higher risk of an adverse event. Approach and Content: The purpose of this review is to provide an overview of the pathophysiology and clinical and analytical characteristics of several biomarkers that may have potential clinical utility to identify ACS patients. These biomarkers (myeloperoxidase, metalloproteinase-9, soluble CD40 ligand, pregnancy-associated plasma protein A, choline, ischemia-modified albumin, unbound free fatty acids, glycogen phosphorylase isoenzyme BB, and placental growth factor) have demonstrated promise and need to be more thoroughly evaluated for commercial development for implementation into routine clinical and laboratory practice. Summary: Specifications that have been addressed for cardiac troponins and natriuretic peptides will need to be addressed with the same scrutiny for the biomarkers discussed in this review. They include validating analytical imprecision and detection limits, calibrator characterization, assay specificity and standardization, preanalytical issues, and appropriate reference interval studies. Crossing boundaries from research to clinical application will require replication in multiple settings and experimental evidence supporting a pathophysiologic role and, ideally, interventional trials demonstrating that monitoring single or multiple biomarkers improves outcomes.

Original languageEnglish (US)
Pages (from-to)810-824
Number of pages15
JournalClinical chemistry
Volume51
Issue number5
DOIs
StatePublished - May 1 2005

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome'. Together they form a unique fingerprint.

  • Cite this

    Apple, F. S., Wu, A. H. A., Mair, J., Ravkilde, J., Panteghini, M., Tate, J., Pagani, F., Christenson, R. H., Mockel, M., Danne, O., & Jaffe, A. S. (2005). Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical chemistry, 51(5), 810-824. https://doi.org/10.1373/clinchem.2004.046292